Efficacy of Closed-loop Insulin Therapy in Prepubertal Child in Free-life (FREELIFE-KID)

Assessment of the Efficacy of Closed-loop Insulin Therapy (Artificial Pancreas) on the Control of Type 1 Diabetes in Prepubertal Child in Free-life: Comparison Between Nocturnal and 24-hour Use on 18 Weeks, Followed by an Extension on 18 Weeks

The study is a randomized trial preceded by a run-in period and followed by a non-randomized study extension. After 3 weeks of outpatient use of study pump (1 week) and study pump+CGM (2weeks) as run-in period, patient and parents will be admitted for 4-hour training to closed-loop (AP) mode. Following randomization (1:1), patient will be allocated to '24-hour' use of AP or 'dinner and overnight AP mode/day time pump and CGM use' for the next 18-week period. At 18-week visit, a study extension for a further 18-week period will be initiated. AP mode that will be prescribed to all patients will depend from an independent DSMB decision based upon study safety data collected after 6 and 12 weeks from the first 30 included patients. Visits will occur at week 27 (safety follow-up) and 36 (final visit).

Study Overview

• Status: Active, not recruiting
• Conditions: Type 1 Diabetes Mellitus in Prepubertal Children
• Intervention / Treatment: Device: Closed-loop insulin infusion driven by continuous glucose monitoring through an algorithm, in free-life conditions

Detailed Description

The study is a randomized trial preceded by a run-in period and followed by a non-randomized study extension. After 3 weeks of outpatient use of study pump (1 week) and study pump+CGM (2weeks) as run-in period, patient and parents will be admitted for 4-hour training to closed-loop (AP) mode. Following randomization (1:1), patient will be allocated to '24-hour' use of AP or 'dinner and overnight AP mode/day time pump and CGM use' for the next 18-week period. A hotline phone number will be given to the patient and parents so that they can contact the study staff as needed. A logbook will be provided to collect details about hypoglycemic and hyperglycemic episodes, physical activity and noticeable events. Phone calls will be scheduled between investigator and patient+parents 48 hours, 1 week and 2 weeks after AP mode initiation. Potential misbehaviors will be corrected and all questions answered. If needed, AP parameters may be revised and reconfigured. Hospital visits will be scheduled 6, 12 and 18 weeks after AP mode initiation for the same purposes, plus HbA1c measurement at week 12 and 18. At 18-week visit, a study extension for a further 18-week period will be initiated. AP mode that will be prescribed to all patients will depend from an independent DSMB decision based upon study safety data collected after 6 and 12 weeks from the first 30 included patients. Visits will occur at week 27 (safety follow-up) and 36 (final visit).

• Study Type: Interventional
• Enrollment (Actual): 122
• Phase: Not Applicable

Contacts and Locations

Study Locations

• France
  • Montpellier, France, 34295
    • Montpellier University Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 6 years to 12 years (Child)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Treatment of diabetes by insulin pump since > 6 months
• HbA1c level < 10%

Exclusion Criteria:

• Unwillingness of one parent or the legally responsible party to participate in insulin treatment
• Any associated chronic disease or therapy (except insulin) affecting glucose metabolism

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Closed-loop insulin delivery 24/7, day and night; Closed-loop subcutaneous insulin infusion driven by continuous glucose monitoring through an algorithm	Device: Closed-loop insulin infusion driven by continuous glucose monitoring through an algorithm, in free-life conditions; Continuous subcutaneous insulin infusion according to an automated algorithm from continuous glucose monitoring data; Other Names: Artificial pancreas
Other: Closed-loop insulin delivery 7/7, dinner and night; Closed-loop subcutaneous insulin infusion driven by continuous glucose monitoring through an algorithm	Device: Closed-loop insulin infusion driven by continuous glucose monitoring through an algorithm, in free-life conditions; Continuous subcutaneous insulin infusion according to an automated algorithm from continuous glucose monitoring data; Other Names: Artificial pancreas

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percent of time spent in the 70-180 mg/dl glucose range assessed on daily CGM data	% time blood glucose in 70-180 mg/dl range	18 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percent of time spent with glucose level < 70, 60 and 50 mg/dl, assessed on daily CGM data	Percent time while blood glucose is kept in safe 70-180 mg/dl range	18 and 36 weeks
Percent of time spent with glucose level > 180 and 300 mg/dl, assessed on daily CGM data	Percent time while blood glucose is kept in safe 70-180 mg/dl range	18 and 36 weeks
Percent of time spent in the 70-140 mg/dl glucose range assessed on daily CGM data	Percent time while blood glucose is kept in safe 70-180 mg/dl range	18 and 36 weeks
Mean glucose level assessed on daily CGM data	CGM data will be used to calculate daily glucose mean to assess the efficacy of the algorithm on glucose control.	18 and 36 weeks
HbA1c level measured at week 12, 18, 27 and 36	Levels of glycated hemoglobin will be measured at different time intervals to assess the clinical impact of the use of the algorithm on patient diabetes.	12,18, 27 and 36 weeks
Number of needed interventions by the patients or care providers to treat hypoglycemia	A logbook will be used all along the study by patients to record carbs intake in case of hypoglycemia. If patient required further assistance, care provider who will record third parties intervention.	18 and 36 weeks
Percent of time with AP functional, discriminating between each component failure modes	Percent time while blood glucose is kept in safe 70-180 mg/dl range	18 and 36 weeks
Score of the Artificial Pancreas Acceptance Questionnaire	This questionnaire consists of 15 affirmations about the use of AP and patient can answer in a scale from 0 (do not agree) to 6 (totally agree). The global score is calculated by the sum of all answers. A high score means a good acceptation of the system. There is no subscale.	18 and 36 weeks

Collaborators and Investigators

• Sponsor: University Hospital, Montpellier
• Investigators: Principal Investigator: Eric M RENARD, MD, PhD, Montpellier University Hospital

Study record dates

Study Major Dates

• Study Start (Actual): November 5, 2018
• Primary Completion (Anticipated): September 5, 2022
• Study Completion (Anticipated): May 5, 2023

Study Registration Dates

• First Submitted: November 5, 2018
• First Submitted That Met QC Criteria: November 9, 2018
• First Posted (Actual): November 13, 2018

Study Record Updates

• Last Update Posted (Actual): December 16, 2021
• Last Update Submitted That Met QC Criteria: December 15, 2021
• Last Verified: December 1, 2021

More Information

Terms related to this study

• Keywords: Type 1 diabetes; Closed-loop insulin infusion; Prepubertal children
• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Immune System Diseases; Autoimmune Diseases; Endocrine System Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 1; Gastrointestinal Agents; Pancrelipase
• Other Study ID Numbers: UF 7580

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No